mGBP8 Inhibitors
Chemical inhibitors of mGBP8 can function by interfering with various cellular processes and pathways that are crucial for the protein's activity. Amiloride disrupts pH regulation by inhibiting the Na+/H+ exchange, which is essential for maintaining the specific pH required for mGBP8's GTPase activity. Similarly, clofazimine can inhibit mGBP8 by altering membrane dynamics due to its interaction with the lipid bilayer, affecting the membrane potential and related functions that mGBP8 is associated with. Clotrimazole interferes with calcium signaling, a pathway that could be important for mGBP8 regulation, by targeting Ca2+/calmodulin-dependent processes. GW5074 and PD 98059 target the Raf/MEK/ERK and MEK/MAP kinase pathways, respectively, which are potentially involved in the activation and regulation of mGBP8. These inhibitors ultimately lead to reduced activity of mGBP8 by blocking the signaling events that are necessary for its function.
Furthermore, LY294002, by inhibiting PI3K signaling, disrupts a cascade that is implicated in the regulation of mGBP8, thereby decreasing its activity. Rapamycin acts on mTOR, a central regulator of autophagy, which is a process that mGBP8 is known to be involved in, leading to the functional inhibition of mGBP8. W7 and Ro 31-8220, by antagonizing calmodulin and inhibiting protein kinase C, respectively, affect signaling pathways that could regulate mGBP8 activity. U73122's inhibition of phospholipase C (PLC) can also result in the functional inhibition of mGBP8, presuming PLC signaling plays a role in regulating the protein's activity. ML7 and SB203580, by targeting myosin light chain kinase and p38 MAP kinase respectively, can affect cytoskeletal dynamics and inflammatory response mechanisms, thereby influencing mGBP8's role and leading to its inhibition.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride inhibits the Na+/H+ exchange which is crucial for pH regulation. mGBP8 requires a specific pH for its GTPase activity; hence, amiloride indirectly inhibits mGBP8 by disrupting the pH balance necessary for its optimal activity. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Clotrimazole, primarily an antifungal agent, has been shown to inhibit Ca2+/calmodulin-dependent processes. Since mGBP8 activity is potentially regulated by calcium signaling pathways, clotrimazole may inhibit mGBP8 through the disruption of calcium homeostasis. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a Raf kinase inhibitor that can indirectly inhibit mGBP8 by blocking the Raf/MEK/ERK pathway, which may be involved in the regulation of GBPs, including mGBP8, through downstream signaling events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which acts upstream of MAP kinase. Inhibition of MEK, and consequently MAP kinase, can lead to reduced activity of mGBP8, as these kinases may be involved in mGBP8 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K signaling is implicated in the regulation of GBPs, and its inhibition by LY294002 can result in decreased activity of mGBP8 by disrupting the signaling cascade necessary for its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and autophagy. Since mGBP8 is involved in autophagy-related processes, inhibition of mTOR by rapamycin can lead to functional inhibition of mGBP8. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W7 is a calmodulin antagonist. By inhibiting calmodulin, W7 can indirectly inhibit mGBP8, presuming that mGBP8's activity is regulated by calmodulin-mediated signaling pathways. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro 31-8220 is a protein kinase C inhibitor. PKC is implicated in the regulation of multiple cellular processes, including those involving GBPs. Inhibition of PKC can result in the functional inhibition of mGBP8. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML7 is a myosin light chain kinase inhibitor. By inhibiting this kinase, ML7 can affect the cytoskeletal dynamics and vesicular trafficking, processes in which mGBP8 is involved, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. p38 MAP kinase is involved in inflammatory responses and may regulate GBP activity, so inhibition of this kinase can result in functional inhibition of mGBP8. | ||||||